Member Info for Celtic007

Thanks guys
Am I right in saying if our tyk2 for psoriasis was taken over by pharmaceutical company like GSK, that they can only use it to treat psoriasis and not many other auto immune conditions. Silly question I know. Ta

Sareum have applied for CTA for psoriasis for tyk2. Now I expect us to obliterate phase 1,, and very confident will show amazing therapeutic qualities in treating it.

The question if successful how much just this indication in £? Lots .

The science is about to get tested for tyk2 , like it was for chk1.

Views appreciated.

Thanks blastoid but don't know. The market leader will turn one with brilliant potency and less side effects.

Agree sadoldgit. I don't understand the moaning this week. We have applied for CTA in psoriasis trials FFS ...a big market. We are moving forward. People moaning about investor meeting being boring and dull. All that is white noise.....the science will do the talking and don't think that GSK are not watching what sareum are up to. I am so excited about pzifer psoriasis tyk2 trial data September ......

Let the trials commence and they shall soon. All the rest is nonsense. If the science is great that will do the talking. Never mind the PR and publicity. Nothing beats the science

Utah...."just think those employed to fill this board with information are winding it up a bit".

Are you talking about yourself and other derampers? You are a constant deramper of this share.

You have got to be blind if you cannot see momentous improvement in the company's climb to get drug to market.

Exactly what I thought. Renaming chk1. Why mention this if not interested? Stood out.
"The two additional assets are currently being evaluated by the team to determine future development plan".

Good to hear.....GSK will not mess about

I do wonder, if we been advised to go for psoriasis as first trial by clever advisers. Scare the living daylights out of nearest best selling rivals, if they let this get through p1, the price goes up and do will interest.

Best to take us out now. Once you are seen for your potential, price goes up astronomically. Van dyke, the best defender in the world ,played at Celtic and went below raders of big boys, but Southampton saw potential and made move and by the time the penny dropped with big boys, the transfer value rocketed to most expensive defender ever!!

A very good analogy

Good post with a lot of scientific background. I am sure, humira and OTEZLA makers be worried. A new kid on the block. I am convinced that we will kick both their backsides in trials. £2bn equated to nearly £40 on just one molecules.

The first CTA for tyk2 was going to be crucial, and looks like we gone after the right one.

Hi ahfam. This is what I said the other day. All these top selling medicines coming off patent , will be costly. I have not been surprised we are going after psoriasis, as the science data shown has been good. September be a big month, as pzifer be giving their readout, I think.

Brilliant first I dictation to go for, and one I expect us to kick butt.

I am still going for £14 to £20....but the longer it's left alone, value goes up. £14_20 is very achievable

Always a pleasure hearing from you WIP. Appreciated, your views.

". We note that category leader TYK2 inhibitor deucravacitinib (Bristol Myers Squibb) is expected to receive the FDA’s verdict in September 2022 for moderate to severe PS, which could have a strong read across for SDC-1801."

This caught my eye. Wonder what Bristol be thinking? They thought they had it to themselves, but nope here we come.

If successful data for them in September, then great for us, but not necessarily for them .

From eddidon

Brilliant post potnak. Today is a momentous day....we are going for psoriasis...a 30billion market.......wowwww. capsules formmmmmmmm.so confident are our scientists about its future. This is the new immune suppressant kids on the block.

We still not seen anything for cancer tyk2....
Lot to be excited about .

Keep patience . Not selling mines for anything under 28p and then will keep good lot.

Be good to hear WIP and thoth and sadoldgit views.....

Hi bluenose. Hope you are ok. Think ,you are a bit harsh on cobalt. He agrees, great RNS. Just the reaction of the market to it.....I am sure a lot of us feel a bit miffed it's not gone up a lot today. However, am content with RNS and know the jigsaw pieces falling into place.

We know when there are derampers here .

Let's all distinguish v
Between constrictive analysis and downright and biased analysis . That biased analysis of course goes both ways.

Just take it in.
1801 has the potential to offer superior efficacy (in psoriasis a market of 30billion per annum) compared to small moliculules commonly AVAILABLE and in DEVELOPMENT inhibiting each of the targets individually.
Essentially we may be ahead of existing and developing competitors.
Yes let that sink in!

As fearg ...says LET THAT FLOW OVER YOU. I REMEMBER A few years ago, many analysts thought that sareum would be marketed for small indications that no one was interested in. NOPE, WE ARE GOING IN THERE, WITH THE BIG BOYS, WITH MOLECULE THAT SHOWS AMAZING QUALITIES IN AUTOIMMUNE. I AM A PHARMACIST AND KNOW OTEZLA MAKER BE WORRIED WITH THIS RNS TODAY. VERY CLEAR, CONFIDENT , AND LETTING US AND THE BIG BOYS KNOW, WHATS COMIMG TO PHARMACY VERY SOON.

SORRY FOR CAPITAL, EXCITED LOL

Yep, so hopefully paperwork all ready for this

Yes, or even that lol ??

Exactly sadoldgit. There is no way will GSK on licence it or sell it. They want to be the top dog in cancer, as their recent manouvers have shown. This drug synergizing other drugs, this they will trial with lots to see different combinations.

They might want it stock, lock, barrel, but I think they would rather take the whole lot. Why sign neymar, when Messi, levodoski available also?

Love your synopsis here sadoldgit.

Here here fearg.....great find HBD.